Creating new treatments for antibiotic-resistant infections
Official title: Development of Therapeutic Products for Antibiotic Resistant Bacteria
Funded at Crestone, INC. · NIH-10919149 · Data updated 2026-11-12
This study is working on a new treatment to help fight infections caused by antibiotic-resistant bacteria, which could give patients more options when current medicines don't work.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Crestone, INC. NIH-funded |
| Lab location | 1 site (Boulder, United States) |
| Project start | July 1, 2020 |
| Project end | July 9, 2025 |
| Funding year | 2023 |
| Award (this year) | $2,665,864 |
| NIH project number | 75N93020C00020-P00008-9999-1 |
| Project ID | NIH-10919149 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from infections caused by antibiotic-resistant bacteria.
✕Less likely to help
Patients with infections that are not caused by antibiotic-resistant bacteria may not benefit from this research.
What this research studies
This research focuses on developing a new therapeutic product aimed at combating antibiotic-resistant bacteria, which are a significant threat to public health. The project involves a series of steps including preclinical testing, optimizing the chemistry of the therapeutic agent, and ensuring it can be manufactured safely and effectively. Patients may benefit from this research as it seeks to provide new treatment options for infections that currently have limited or no effective therapies. The research will also assess the safety and efficacy of the new treatment in clinical settings.
Why it matters
Potential benefit: If successful, this research could lead to new and effective treatments for infections caused by antibiotic-resistant bacteria.
How similar studies have gone: Other research has shown promise in developing treatments for antibiotic-resistant infections, indicating that this approach has potential for success.
Where this research is happening
-
Crestone, INC.
Boulder, United States Active
Researchers
- Principal investigator: Ochsner, Urs — Crestone, INC.
- Study coordinator: Ochsner, Urs
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.